Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Fig. 2

Results from identification of clinical and regulatory variables. Descriptive results of clinical and regulatory variables of ODs authorised in Spain for treating rare diseases and approved by the European Commission between 2003 & 2019 (n = 94). PASS, obligation by the EMA to conduct a Post-authorisation safety study; No PASS, no obligation by the EMA to conduct a Post-authorisation safety study

Back to article page